MX2023001445A - Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4. - Google Patents

Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.

Info

Publication number
MX2023001445A
MX2023001445A MX2023001445A MX2023001445A MX2023001445A MX 2023001445 A MX2023001445 A MX 2023001445A MX 2023001445 A MX2023001445 A MX 2023001445A MX 2023001445 A MX2023001445 A MX 2023001445A MX 2023001445 A MX2023001445 A MX 2023001445A
Authority
MX
Mexico
Prior art keywords
smarca2
smarca4
compounds
degraders
substituted pyridazine
Prior art date
Application number
MX2023001445A
Other languages
English (en)
Spanish (es)
Inventor
Chandrasekhar Abbineni
Subhendu Mukherjee
Susanta Samajdar
Bilash Kuila
Gore Suraj Tatyasaheb
Original Assignee
Aurigene Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Oncology Ltd filed Critical Aurigene Oncology Ltd
Publication of MX2023001445A publication Critical patent/MX2023001445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023001445A 2020-08-04 2021-08-03 Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4. MX2023001445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041033326 2020-08-04
PCT/IB2021/057089 WO2022029617A1 (en) 2020-08-04 2021-08-03 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

Publications (1)

Publication Number Publication Date
MX2023001445A true MX2023001445A (es) 2023-05-08

Family

ID=80117730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001445A MX2023001445A (es) 2020-08-04 2021-08-03 Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4.

Country Status (11)

Country Link
US (2) US12570650B2 (cg-RX-API-DMAC7.html)
EP (1) EP4192835A4 (cg-RX-API-DMAC7.html)
JP (2) JP7857914B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230061349A (cg-RX-API-DMAC7.html)
CN (1) CN116529250A (cg-RX-API-DMAC7.html)
AU (1) AU2021320052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002089A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188024A1 (cg-RX-API-DMAC7.html)
IL (1) IL300387A (cg-RX-API-DMAC7.html)
MX (1) MX2023001445A (cg-RX-API-DMAC7.html)
WO (1) WO2022029617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
AU2024348074A1 (en) 2023-09-27 2026-04-30 Haisco Pharmaceutical Group Co., Ltd. Pyrazole carboxylic acid derivative and use thereof in medicine
WO2025196686A1 (en) * 2024-03-20 2025-09-25 Aurigene Oncology Limited Fused bicyclic compounds as smarca2 and/or smarca4 degraders
CN119874808B (zh) * 2025-01-02 2026-04-17 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952188A1 (en) * 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3319944A4 (en) * 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20190140438A (ko) * 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
AU2019249849C1 (en) 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
CA3167166A1 (en) * 2020-01-10 2021-07-15 Amgen Inc. Smarca2-vhl degraders

Also Published As

Publication number Publication date
JP2026082834A (ja) 2026-05-19
WO2022029617A1 (en) 2022-02-10
EP4192835A1 (en) 2023-06-14
CA3188024A1 (en) 2022-02-10
IL300387A (en) 2023-04-01
BR112023002089A2 (pt) 2023-02-28
JP7857914B2 (ja) 2026-05-13
US20240018134A1 (en) 2024-01-18
AU2021320052A1 (en) 2023-03-23
US12570650B2 (en) 2026-03-10
CN116529250A (zh) 2023-08-01
EP4192835A4 (en) 2024-08-21
JP2023536504A (ja) 2023-08-25
US20260184705A1 (en) 2026-07-02
KR20230061349A (ko) 2023-05-08

Similar Documents

Publication Publication Date Title
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
BR112023002089A2 (pt) Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4
PH12020551305A1 (en) Pharmaceutical Compounds
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022015857A (es) Compuestos de dihidroquinolin sulfonamida de heteroalquilo.
EP4566675A3 (en) Heterocyclic compounds as immunomodulators
MX2019013954A (es) Inhibidores covalentes de kras.
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MX2023002907A (es) Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.
PH12018501920A1 (en) Bromodomain inhibitors
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
GEAP202516634A (en) Heteroaryl compounds for the treatment of pain
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2021007247A (es) Derivados de rapamicina.
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2025014320A (es) Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
EP4640220A3 (en) Orally disintegrating pharmaceutical compositions of apixaban
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
EP4342542A3 (en) Combination of regorafenib and nivolumab for treating cancer
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors